Skip to main content

Bexsero

NDC 58160-976 · GlaxoSmithKline Biologicals SA

Generic nameNEISSERIA MENINGITIDIS SEROGROUP B NHBA FUSION PROTEIN ANTIGEN, NEISSERIA MENINGITIDIS SEROGROUP B FHBP FUSION PROTEIN ANTIGEN and NEISSERIA MENINGITIDIS SEROGROUP B NADA PROTEIN ANTIGEN
Dosage formINJECTION, SUSPENSION
RouteINTRAMUSCULAR
Active ingredient(s)NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN ANTIGEN, NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN ANTIGEN, NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN ANTIGEN, NEISSERIA MENINGITIDIS GROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE ANTIGEN
Strength50; 50; 50; 25 ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL
Marketing categoryBLA

Packages

58160-976-20 — 10 SYRINGE in 1 CARTON (58160-976-20) / .5 mL in 1 SYRINGE (58160-976-02)

From the FDA National Drug Code Directory, retrieved August 24, 2026. Product listings are submitted by labelers; FDA does not verify them.

Read from: FDA National Drug Code Directory, product.txt and package.txt (accessdata.fda.gov/cder/ndctext.zip) — Snapshot retrieved 2026-08-24, loaded 2026-08-24; CMS Medicare Part B Drug Average Sales Price (ASP) Pricing Files (cms.gov/medicare/payment/part-b-drugs/asp-pricing-files) -- the NDC-HCPCS crosswalk and Part B payment limit files — 2026 Q3 (July 2026 release). All data sources · How to read the labels